* Announces that patient enrollment is complete for the
phase 3 studies of JZP-110 evaluating excessive sleepiness in
obstructive Sleep Apnea
The post BRIEF-Jazz Pharmaceuticals announces that patient enrollment is complete for phase 3 studies of JZP-110 appeared first on NASDAQ.